<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-title>BMC Neurology</journal-title><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2377-5-19</article-id><article-id pub-id-type="pmid">16255771</article-id><article-id pub-id-type="doi">10.1186/1471-2377-5-19</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Early B-cell Factor gene association with multiple sclerosis in the Spanish population</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Mart&#x000ed;nez</surname><given-names>Alfonso</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>alfmdoncel@terra.es</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Mas</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>anamasfontao@hotmail.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>de las Heras</surname><given-names>Virginia</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>v_delasheras@yahoo.es</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Arroyo</surname><given-names>Rafael</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>rafarro@terra.es</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Fern&#x000e1;ndez-Arquero</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mfernandeza.hcsc@salud.madrid.org</email></contrib><contrib id="A6" corresp="yes" contrib-type="author"><name><surname>de la Concha</surname><given-names>Emilio G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>egomezdela.hcsc@salud.madrid.org</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Urcelay</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>eurcelay@hcsc.es</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Clinical Immunology, Hospital Clinico San Carlos, Madrid, Spain</aff><aff id="I2"><label>2</label>Department of Neurology, Hospital Clinico San Carlos, Madrid, Spain</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>28</day><month>10</month><year>2005</year></pub-date><volume>5</volume><fpage>19</fpage><lpage>19</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2377/5/19"/><history><date date-type="received"><day>9</day><month>8</month><year>2005</year></date><date date-type="accepted"><day>28</day><month>10</month><year>2005</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 Mart&#x000ed;nez et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Mart&#x000ed;nez et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Mart&#x000ed;nez Alfonso alfmdoncel@terra.es </dc:author><dc:title> Early B-cell Factor gene association with multiple sclerosis in the Spanish population </dc:title><dc:date>2005</dc:date><dcterms:bibliographicCitation>BMC Neurology 5(1): 19-. (2005)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2377(2005)5:1&#x0003c;19&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2377</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The etiology of multiple sclerosis (MS) is at present not fully elucidated, although it is considered to result from the interaction of environmental and genetic susceptibility factors. In this work we aimed at testing the Early B-cell Factor (<italic>EBF1</italic>) gene as a functional and positional candidate risk factor for this neurological disease. Axonal damage is a hallmark for multiple sclerosis clinical disability and EBF plays an evolutionarily conserved role in the expression of proteins essential for axonal pathfinding. Failure of B-cell differentiation was found in EBF-deficient mice and involvement of B-lymphocytes in MS has been suggested from their presence in cerebrospinal fluid and lesions of patients.</p></sec><sec sec-type="methods"><title>Methods</title><p>The role of the <italic>EBF1 </italic>gene in multiple sclerosis susceptibility was analyzed by performing a case-control study with 356 multiple sclerosis patients and 540 ethnically matched controls comparing the <italic>EBF1 </italic>polymorphism rs1368297 and the microsatellite <italic>D5S2038.</italic></p></sec><sec><title>Results</title><p>Significant association of an <italic>EBF1</italic>-intronic polymorphism (rs1368297, A vs. T: p = 0.02; OR = 1.26 and AA vs. [TA+TT]: p = 0.02; OR = 1.39) was discovered. This association was even stronger after stratification for the well-established risk factor of multiple sclerosis in the Major Histocompatibility Complex, DRB1*1501 (AA vs. [TA+TT]: p = 0.005; OR = 1.78). A trend for association in the case-control study of another <italic>EBF1 </italic>marker, the allele 5 of the very informative microsatellite <italic>D5S2038</italic>, was corroborated by Transmission Disequilibrium Test of 53 trios (p = 0.03).</p></sec><sec><title>Conclusion</title><p>Our data support <italic>EBF1 </italic>gene association with MS pathogenesis in the Spanish white population. Two genetic markers within the <italic>EBF1 </italic>gene have been found associated with this neurological disease, indicative either of their causative role or that of some other polymorphism in linkage disequilibrium with them.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Multiple sclerosis (MS) is one of the most common neurological diseases of young adults in Europe and North America [<xref ref-type="bibr" rid="B1">1</xref>]. Similarly to other common complex diseases, the interplay of genome and environment as MS susceptibility factors seems to determine the final outcome. Its precise etiology is at present unknown, even though the first genetic association with the MHC was published more than thirty years ago [<xref ref-type="bibr" rid="B2">2</xref>]. Genomic screens support the hypothesis that susceptibility to develop MS is determined by multiple genes with small individual contributions. To decipher those combinations of genes resulting in MS is a major goal of research. Association of MS with the <italic>HLA-DRB1*1501-DQB1*0602 </italic>haplotype has been unambiguously demonstrated [<xref ref-type="bibr" rid="B3">3</xref>]. The diversity of the predisposition genes is evident if we consider that the major risk allele <italic>HLA-DRB1*1501 </italic>is present only in 33% of our Spanish MS patients. New susceptibility genes are therefore actively sought worldwide. In the past, candidate gene approaches have successfully revealed associations with disease susceptibility, severity or disease course.</p><p>MS has been traditionally considered an autoimmune demyelinating disorder of the central nervous system (CNS) due to autoreactive T cells on myelin proteins. However, other cells and processes have also been involved in the MS immune attack. A role for B cells in MS pathogenesis has been suggested from their presence in the cerebrospinal fluid and lesions of MS patients [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Axonal degeneration [<xref ref-type="bibr" rid="B6">6</xref>] has been found in early stages of the disease [<xref ref-type="bibr" rid="B7">7</xref>]. Axonal loss is a reliable marker of MS clinical disability [<xref ref-type="bibr" rid="B8">8</xref>], although the mechanism underlying axonal damage in MS remains elusive [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>].</p><p>B cells derive from a common lymphoid progenitor, itself derived from a multipotent bone marrow progenitor. The development of a B lymphocyte comprises multiple stages with sequential expression of genes participating in immunoglobulin gene rearrangements and signaling. B cell development depends on a number of transcription factors [<xref ref-type="bibr" rid="B11">11</xref>] including early B cell factor (EBF), as shown for the dramatic phenotype of EBF-deficient mice [<xref ref-type="bibr" rid="B12">12</xref>]. B cell differentiation to plasma cell in secondary lymphoid organs is an exquisitely regulated process requiring EBF inhibition [<xref ref-type="bibr" rid="B13">13</xref>] and a full recapitulation of this B cell final differentiation has been recently described in the CSF [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>EBF [<xref ref-type="bibr" rid="B15">15</xref>] belongs to a family of proteins present in the animal kingdom, the Collier/Olf1/EBF proteins, and it is also expressed in neural cells of different origins. EBF plays an evolutionarily conserved role in the expression of proteins essential for axonal pathfinding and neuronal differentiation in both sensory and motor neurons [<xref ref-type="bibr" rid="B16">16</xref>]. In addition to the action of the EBF protein in embryonic neural development, it is expressed in the adult nervous system too [<xref ref-type="bibr" rid="B17">17</xref>]. Furthermore, EBF binding activates the Herpes Simplex Virus Type I <italic>ICP0 </italic>(Infected Cell Protein 0) gene promoter, important for productive infection and reactivation from latency [<xref ref-type="bibr" rid="B18">18</xref>]. This virus has been related to MS [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>].</p><p>All this evidence prompted us to determine whether the <italic>EBF1 </italic>gene (coding for the first member of this family cloned in humans), located at chromosome 5q has any role in MS pathogenesis. Unfortunately, no description of functional <italic>EBF1 </italic>polymorphisms exists in the literature, and therefore two markers were selected based on strictly genetic parameters. The first is the highly polymorphic D5S2038 microsatellite mapping to the <italic>EBF1 </italic>gene and the second an intronic single nucleotide polymorphism (rs1368297). The present work shows association of these markers with MS in the Spanish cohorts tested. Most probably MS is consequence of the interaction of a limited number of genetic and environmental risk factors in a patient, which may vary from those present in other patients.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients and controls</title><p>Three hundred and fifty six consecutively recruited MS patients from a single center and 540 healthy controls, mainly blood donors and staff, were included in a case-control study approved by the Hospital Ethical committee. The MS diagnosis was established based on the Poser criteria [<xref ref-type="bibr" rid="B21">21</xref>] and most of these patients have been described in previous studies from our group [<xref ref-type="bibr" rid="B22">22</xref>].</p></sec><sec><title>Genotyping</title><p>D5S2038 microsatellite was amplified with annealing temperature of 56&#x000b0;C using the following set of primers:</p><p>Forward: 5' FAM-GTT CAA ATC TTG CCT TTG CC-3'</p><p>Reverse: 5'-GCC ATT GCT TTG TTT ATG CA-3'</p><p>Samples were subsequently denatured and run on an ABI Prism 3100 automatic sequencer (Applied Biosystems, Foster City, CA, USA). Each sample included an internal size standard in order to achieve a highly consistent measure and the results were analyzed using the GeneScan software (Applied Biosystems) and the Local Southern method.</p><p>The <italic>EBF1 </italic>polymorphism (rs1368297) was analyzed by TaqMan Assays-on-Demand (C___2085085_10) from Applied Biosystems, following manufacturer suggestions.</p><p>Both genetic markers conformed to Hardy-Weinberg equilibrium in the control population.</p></sec><sec><title>Statistical analysis</title><p>Allele and genotype frequencies in patients and controls were compared by the &#x003c7;<sup>2 </sup>test; p values were considered significant at a level of &#x0003c; 0.05. Odds ratio (OR) and p values were calculated using a standard computer package (Epi Info v. 6.02, CDC, Atlanta, USA). The power of the study for the SNP analyzed is above 80% considering a relative risk of 1.4 and the observed allelic frequency of 0.5 at the standard significance level of 0.05.</p></sec></sec><sec><title>Results</title><p>As microsatellites are very polymorphic and informative genetic markers, we decided to select one within the <italic>EBF1 </italic>gene, <italic>D5S2038</italic>, and to study its allele distribution in our cohorts. The case-control analysis of this microsatellite in 356 MS patients and 540 healthy controls yielded the results summarized in Table <xref ref-type="table" rid="T1">1</xref>. As shown, the only allele displaying a trend for association was <italic>D5S2038*5</italic>, while the frequency of the other ten alleles did not change significantly when patients and controls were compared. No differences were observed when different clinical forms were compared (primary progressive vs relapsing-remitting/secondary progressive). Considering these case-control results, we performed a Transmission Disequilibrium Test (TDT) with 53 trios formed by the patients and their progenitors. Distorted transmission of the <italic>D5S2038*5 </italic>was observed too (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Allele frequencies of <italic>EBF1 </italic>microsatellite D5S2038 in MS patients and healthy controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><italic>EBF1 </italic>D5S2038</td><td align="center">Controls (n = 540)</td><td align="center">MS patients (n = 356)</td><td align="center">p</td></tr></thead><tbody><tr><td align="center">1</td><td align="center">2</td><td align="center">2</td><td align="center">0.99</td></tr><tr><td align="center">2</td><td align="center">27</td><td align="center">15</td><td align="center">0.58</td></tr><tr><td align="center">3</td><td align="center">55</td><td align="center">36</td><td align="center">0.97</td></tr><tr><td align="center">4</td><td align="center">272</td><td align="center">176</td><td align="center">0.78</td></tr><tr><td align="center">5*</td><td align="center">246</td><td align="center">183</td><td align="center">0.08</td></tr><tr><td align="center">6</td><td align="center">119</td><td align="center">81</td><td align="center">0.80</td></tr><tr><td align="center">7</td><td align="center">79</td><td align="center">47</td><td align="center">0.54</td></tr><tr><td align="center">8</td><td align="center">146</td><td align="center">94</td><td align="center">0.83</td></tr><tr><td align="center">9</td><td align="center">8</td><td align="center">7</td><td align="center">0.57</td></tr><tr><td align="center">10</td><td align="center">7</td><td align="center">4</td><td align="center">1.00</td></tr><tr><td align="center">11</td><td align="center">3</td><td align="center">0</td><td align="center">0.28</td></tr></tbody></table><table-wrap-foot><p>* p = 0.08; OR (95%CI) = 1.26 (0.96&#x02013;1.67)</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Transmission Disequilibrium Test (TDT) of <italic>EBF1 </italic>microsatellite D5S2038 in trios (MS patient and progenitors).</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><italic>EBF1 </italic>D5S2038</td><td align="center">Transmitted</td><td align="center">Non transmitted</td><td align="center">p</td></tr></thead><tbody><tr><td align="center">3</td><td align="center">5</td><td align="center">9</td><td align="center">0.91</td></tr><tr><td align="center">4</td><td align="center">23</td><td align="center">11</td><td align="center">0.44</td></tr><tr><td align="center">5</td><td align="center">28</td><td align="center">15</td><td align="center">0.03</td></tr><tr><td align="center">6</td><td align="center">3</td><td align="center">8</td><td align="center">0.96</td></tr><tr><td align="center">7</td><td align="center">3</td><td align="center">7</td><td align="center">0.94</td></tr><tr><td align="center">8</td><td align="center">11</td><td align="center">10</td><td align="center">0.50</td></tr><tr><td align="center">9</td><td align="center">0</td><td align="center">2</td><td align="center">1.00</td></tr><tr><td align="center">10</td><td align="center">1</td><td align="center">1</td><td align="center">0.75</td></tr></tbody></table></table-wrap><p>We pursued to check another polymorphism within the <italic>EBF1 </italic>gene in order to provide more evidence in support of the association of the gene with MS. Data corresponding to the allele and genotype frequencies of the intronic SNP rs1368297 are found in Table <xref ref-type="table" rid="T3">3</xref>. Allele A was significantly increased in the diseased population and, under a recessive inheritance model, the AA homozygous genotype also conferred predisposition to MS. Moreover, the ratio of risk: non-risk homozygous genotypes was significantly higher among multiple sclerosis patients (AA: TT: p = 0.03; OR [95%CI] = 1.56 [1.03&#x02013;2.37]).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Allele and genotype frequencies of the <italic>EBF1 </italic>polymorphism in multiple sclerosis patients and controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">EBF rs1368297</td><td align="center">AA</td><td align="center">AT</td><td align="center">TT</td><td align="center">A</td><td align="center">T</td></tr></thead><tbody><tr><td align="center">MS patients</td><td align="center">125</td><td align="center">168</td><td align="center">58</td><td align="center">418</td><td align="center">284</td></tr><tr><td align="center">(n = 351)</td><td align="center">35.6%</td><td align="center">47.8%</td><td align="center">16.5%</td><td align="center">59.5%</td><td align="center">40.5%</td></tr><tr><td align="center">Controls</td><td align="center">149</td><td align="center">267</td><td align="center">108</td><td align="center">565</td><td align="center">483</td></tr><tr><td align="center">(n = 524)</td><td align="center">28.4%</td><td align="center">50.9%</td><td align="center">20.6%</td><td align="center">53.9%</td><td align="center">46.1%</td></tr></tbody></table><table-wrap-foot><p>AA vs. (AT+TT): p = 0.02; OR (95% CI) = 1.39 (1.03&#x02013;1.88).</p><p>A vs. T: p = 0.02; OR (95% CI) = 1.26 (1.03&#x02013;1.53).</p></table-wrap-foot></table-wrap><p>The MS cohort was stratified for the well-known MHC susceptibility factor <italic>DRB1*1501 </italic>and the difference between <italic>DRB1*1501</italic><sup>+ </sup>patients and healthy controls was even stronger than in the unconditioned analysis (Table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Genotype frequencies of the <italic>EBF1 </italic>polymorphism in <italic>HLA-DRB1*1501 </italic>positive and negative multiple sclerosis patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">EBF rs1368297</td><td align="center">AA</td><td align="center">AT</td><td align="center">TT</td><td align="center">A</td><td align="center">T</td></tr></thead><tbody><tr><td align="center">DRB1*1501<sup>+ </sup>MS patients*</td><td align="center">51</td><td align="center">53</td><td align="center">19</td><td align="center">155</td><td align="center">91</td></tr><tr><td align="center">(n = 123)</td><td align="center">41.5%</td><td align="center">43.1%</td><td align="center">15.4%</td><td align="center">63%</td><td align="center">37%</td></tr><tr><td align="center">DRB1*1501<sup>- </sup>MS patients</td><td align="center">74</td><td align="center">115</td><td align="center">39</td><td align="center">263</td><td align="center">193</td></tr><tr><td align="center">(n = 228)</td><td align="center">32.5%</td><td align="center">50.4%</td><td align="center">17.1%</td><td align="center">57.7%</td><td align="center">42.3%</td></tr><tr><td align="center">Controls</td><td align="center">149</td><td align="center">267</td><td align="center">108</td><td align="center">565</td><td align="center">483</td></tr><tr><td align="center">(n = 524)</td><td align="center">28.4%</td><td align="center">50.9%</td><td align="center">20.6%</td><td align="center">53.9%</td><td align="center">46.1%</td></tr></tbody></table><table-wrap-foot><p>* AA vs. (AT+TT): p = 0.005; OR (95% CI) = 1.78 (1.16&#x02013;2.73)</p><p>A vs. T: p = 0.01; OR (95% CI) = 1.46 (1.08&#x02013;1.96)</p></table-wrap-foot></table-wrap><p>Finally, when simultaneous carriage of both susceptibility alleles, <italic>D5S2038*5 </italic>and <italic>EBF </italic>SNP*A, was compared between MS patients and controls an increment was observed within the diseased cohort (p = 0.03; OR [95%CI] = 1.38 [1.03&#x02013;1.84]).</p></sec><sec><title>Discussion</title><p>Information from genomic screens proposed the 5q chromosomal region as linked to MS [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. Additionally, a recent report compared chromosomal regions, quantitative trait loci (QTLs), of MS patients and of EAE animal models and, by analysis of sequence similarities, defined consensus genes potentially conferring susceptibility to MS [<xref ref-type="bibr" rid="B25">25</xref>]. Among them, the <italic>EBF1 </italic>gene in chromosome 5q34 was cited, providing positional evidence of the role of this gene in MS predisposition.</p><p>Moreover, the simultaneous measurement of thousands of genes upregulated by EBF through microarray technology allowed the detection of 3.5-fold increase in the expression of interleukin 6 (IL-6) and of the microtubule associated protein tau listed among the top twelve most abundant transcripts [<xref ref-type="bibr" rid="B26">26</xref>]. IL-6 has been detected in MS brain and its expression elevated in cerebrospinal fluid of patients [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. IL-6 knockout mice showed resistance to induced EAE, too [<xref ref-type="bibr" rid="B29">29</xref>]. The physiological function of tau is to bind to and stabilize microtubules [<xref ref-type="bibr" rid="B30">30</xref>] and it is involved in regulation of axonal transport [<xref ref-type="bibr" rid="B31">31</xref>]. Tau protein concentration has been found repeatedly increased in cerebrospinal fluid of MS patients [<xref ref-type="bibr" rid="B32">32</xref>]. Also morphological examination demonstrated accumulation of amorphous deposits of abnormally phosphorylated tau in the cell body and axons of neurons within demyelinating plaques in EAE [<xref ref-type="bibr" rid="B33">33</xref>]. Axonopathy has been involved recently in early stages of the pathogenesis of another neurological disease, Alzheimer's disease [<xref ref-type="bibr" rid="B34">34</xref>]. Aberrant accumulation of proteins may be crucial to the impairment of axonal transport.</p><p>Our results evidence association of the <italic>EBF1 </italic>gene with MS. There are no functional studies of these gene polymorphisms, although it was cloned more than a decade ago. However, several reports showed transcriptional regulatory elements located in intronic regions of different genes [<xref ref-type="bibr" rid="B35">35</xref>-<xref ref-type="bibr" rid="B38">38</xref>]. In fact, the susceptibility allele of this EBF-intronic polymorphism allows the putative binding of an AP-1 transcription factor and this binding site is disrupted in the presence of the T allele (as predicted by TFSEARCH ver 1.3). Functional studies of <italic>EBF1 </italic>will aid in clarifying the role of this gene in MS pathogenesis. Nonetheless, the polymorphisms studied in this work act as genetic markers, which could potentially be the etiologic variants or be in linkage disequilibrium with them.</p><p>The EBF prototypical regulatory activity in B lymphocyte differentiation alone justifies the functional involvement of the <italic>EBF1 </italic>gene in an autoimmune disease as MS. Increasing evidence supports the role in MS disease course of IgM antibodies [<xref ref-type="bibr" rid="B39">39</xref>] produced by CD5<sup>+ </sup>B-lymphocytes, that are elevated in CSF of patients with aggressive forms of MS [<xref ref-type="bibr" rid="B40">40</xref>]. These natural IgM antibodies recognize myelin antigens and are strong complement activators [<xref ref-type="bibr" rid="B41">41</xref>]. Both, antibodies and complement, have been shown to contribute to MS disability through demyelination and axonal damage [<xref ref-type="bibr" rid="B42">42</xref>]. IgG antibodies with hypermutated V regions have been also described [<xref ref-type="bibr" rid="B43">43</xref>]. Moreover, <italic>EBF1 </italic>is a potent modulator of adipogenesis [<xref ref-type="bibr" rid="B44">44</xref>] and the IgM bands in cerebrospinal fluid of MS patients were directed against myelin lipids [<xref ref-type="bibr" rid="B40">40</xref>].</p></sec><sec><title>Conclusion</title><p>Our data suggest that the <italic>EBF1 </italic>gene involved in B-cell development, adipogenesis and axonal damage play a causative role in MS. Many mechanistic ties between axonal damage, tau pathology, intrathecal B1 subpopulation responsible for IgM secretion, conventional B cells, and the <italic>EBF1 </italic>gene role in MS susceptibility could be thought up. Confirmation in an independent cohort would substantiate our hypothesis about the implications of this gene in MS. Further understanding of the MS pathogenesis will help in the selection of therapeutic targets and characterization of the specific susceptibility genetic pattern in an individual will aid in a better diagnosis and ultimately in achievement of a personalized therapy.</p></sec><sec><title>List of abbreviations used</title><p>Early B-cell Factor gene (<italic>EBF1</italic>).</p><p>Multiple sclerosis (MS).</p><p>Major Histocompatibility Complex (MHC).</p><p>Human leukocyte antigen (HLA).</p><p>Central nervous system (CNS).</p><p>Infected Cell Protein 0 (ICP0).</p><p>Transmission Disequilibrium Test (TDT).</p><p>Single nucleotide polymorphism (SNP).</p><p>Quantitative trait loci (QTLs).</p><p>Experimental autoimmune encephalitis (EAE).</p><p>Odds ratio (OR).</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>AMart&#x000ed;nez carried out the genotyping of some samples and participated in the statistical analysis and writing of the manuscript.</p><p>AMas carried out the genotyping of most of the patients and a great part of the controls and participated in the statistical analysis.</p><p>VdlH made the diagnosis, participated in the recollection of samples and collaborated in the statistical analysis.</p><p>RA made the diagnosis, participated in the recollection of samples and collaborated in the statistical analysis.</p><p>MFA participated in the coordination of the study and helped to collect the DNA samples and to interpret the data.</p><p>EgdlC participated in the design and coordination of the study and critically revised the article.</p><p>EU conceived of the study and participated in the statistical analysis and drafted the major part of the manuscript.</p><p>All authors have read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2377/5/19/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors thank Carmen Mart&#x000ed;nez for her skilful technical assistance. Elena Urcelay is recipient of a <italic>Ram&#x000f3;n y Cajal </italic>contract of the Spanish Government. Alfonso Mart&#x000ed;nez is recipient of a research contract of the Spanish Health Ministry (CP04/00175). Ana Mas is a fellow of the Alfonso Mart&#x000ed;n Escudero Fundation. The Spanish FIS 04/0991 and the Rodriguez-Pascual Fundation supported this work.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noseworthy</surname><given-names>JH</given-names></name><name><surname>Lucchinetti</surname><given-names>C</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><name><surname>Weinshenker</surname><given-names>BG</given-names></name></person-group><article-title>Multiple sclerosis</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>938</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">11006371</pub-id><pub-id pub-id-type="doi">10.1056/NEJM200009283431307</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jersild</surname><given-names>C</given-names></name><name><surname>Svejgaard</surname><given-names>A</given-names></name><name><surname>Fog</surname><given-names>T</given-names></name></person-group><article-title>HL-A antigens and multiple sclerosis</article-title><source>Lancet</source><year>1972</year><volume>1</volume><fpage>1240</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">4113225</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(72)90962-2</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olerup</surname><given-names>O</given-names></name><name><surname>Hillert</surname><given-names>J</given-names></name></person-group><article-title>HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation</article-title><source>Tissue Antigens</source><year>1991</year><volume>38</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">1926129</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>GP</given-names></name><name><surname>Kraus</surname><given-names>H</given-names></name><name><surname>Burgoon</surname><given-names>MP</given-names></name><name><surname>Smith-Jensen</surname><given-names>T</given-names></name><name><surname>Devlin</surname><given-names>ME</given-names></name><name><surname>Gilden</surname><given-names>DH</given-names></name></person-group><article-title>Restricted use of VH4 germline segments in an acute multiple sclerosis brain</article-title><source>Ann Neurol</source><year>1998</year><volume>43</volume><fpage>236</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">9485065</pub-id><pub-id pub-id-type="doi">10.1002/ana.410430214</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Duquette</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Talbot</surname><given-names>P</given-names></name><name><surname>Poole</surname><given-names>R</given-names></name><name><surname>Antel</surname><given-names>J</given-names></name></person-group><article-title>Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis</article-title><source>J Clin Invest</source><year>1998</year><volume>102</volume><fpage>1045</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">9727074</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trapp</surname><given-names>BD</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Rudick</surname><given-names>R</given-names></name><name><surname>Mork</surname><given-names>S</given-names></name><name><surname>Bo</surname><given-names>L</given-names></name></person-group><article-title>Axonal transection in the lesions of multiple sclerosis</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>278</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">9445407</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199801293380502</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Stefano</surname><given-names>N</given-names></name><name><surname>Narayanan</surname><given-names>S</given-names></name><name><surname>Francis</surname><given-names>GS</given-names></name><name><surname>Arnaoutelis</surname><given-names>R</given-names></name><name><surname>Tartaglia</surname><given-names>MC</given-names></name><name><surname>Antel</surname><given-names>JP</given-names></name><name><surname>Matthews</surname><given-names>PM</given-names></name><name><surname>Arnold</surname><given-names>DL</given-names></name></person-group><article-title>Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability</article-title><source>Arch Neurol</source><year>2001</year><volume>58</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">11176938</pub-id><pub-id pub-id-type="doi">10.1001/archneur.58.1.65</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Stefano</surname><given-names>N</given-names></name><name><surname>Matthews</surname><given-names>PM</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Narayanan</surname><given-names>S</given-names></name><name><surname>Stanley</surname><given-names>J</given-names></name><name><surname>Francis</surname><given-names>GS</given-names></name><name><surname>Antel</surname><given-names>JP</given-names></name><name><surname>Arnold</surname><given-names>DL</given-names></name></person-group><article-title>Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study</article-title><source>Brain</source><year>1998</year><volume>121</volume><fpage>1469</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">9712009</pub-id><pub-id pub-id-type="doi">10.1093/brain/121.8.1469</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pitt</surname><given-names>D</given-names></name><name><surname>Werner</surname><given-names>P</given-names></name><name><surname>Raine</surname><given-names>CS</given-names></name></person-group><article-title>Glutamate excitotoxicity in a model of multiple sclerosis</article-title><source>Nat Med</source><year>2000</year><volume>6</volume><fpage>67</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">10613826</pub-id><pub-id pub-id-type="doi">10.1038/71555</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lappe-Siefke</surname><given-names>C</given-names></name><name><surname>Goebbels</surname><given-names>S</given-names></name><name><surname>Gravel</surname><given-names>M</given-names></name><name><surname>Nicksch</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Braun</surname><given-names>PE</given-names></name><name><surname>Griffiths</surname><given-names>IR</given-names></name><name><surname>Nave</surname><given-names>KA</given-names></name></person-group><article-title>Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination</article-title><source>Nat Genet</source><year>2003</year><volume>33</volume><fpage>366</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">12590258</pub-id><pub-id pub-id-type="doi">10.1038/ng1095</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Busslinger</surname><given-names>M</given-names></name></person-group><article-title>Transcriptional control of early B cell development</article-title><source>Annu Rev Immunol</source><year>2004</year><volume>22</volume><fpage>55</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">15032574</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104807</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Grosschedl</surname><given-names>R</given-names></name></person-group><article-title>Failure of B-cell differentiation in mice lacking the transcription factor EBF</article-title><source>Nature</source><year>1995</year><volume>376</volume><fpage>263</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">7542362</pub-id><pub-id pub-id-type="doi">10.1038/376263a0</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>KI</given-names></name><name><surname>Tunyaplin</surname><given-names>C</given-names></name><name><surname>Calame</surname><given-names>K</given-names></name></person-group><article-title>Transcriptional regulatory cascades controlling plasma cell differentiation</article-title><source>Immunol Rev</source><year>2003</year><volume>194</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">12846804</pub-id><pub-id pub-id-type="doi">10.1034/j.1600-065X.2003.00040.x</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corcione</surname><given-names>A</given-names></name><name><surname>Casazza</surname><given-names>S</given-names></name><name><surname>Ferretti</surname><given-names>E</given-names></name><name><surname>Giunti</surname><given-names>D</given-names></name><name><surname>Zappia</surname><given-names>E</given-names></name><name><surname>Pistorio</surname><given-names>A</given-names></name><name><surname>Gambini</surname><given-names>C</given-names></name><name><surname>Mancardi</surname><given-names>GL</given-names></name><name><surname>Uccelli</surname><given-names>A</given-names></name><name><surname>Pistoia</surname><given-names>V</given-names></name></person-group><article-title>Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>11064</fpage><lpage>11069</lpage><pub-id pub-id-type="pmid">15263096</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0402455101</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>MM</given-names></name><name><surname>Reed</surname><given-names>RR</given-names></name></person-group><article-title>Molecular cloning of the olfactory neuronal transcription factor Olf-1 by genetic selection in yeast</article-title><source>Nature</source><year>1993</year><volume>364</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">8321284</pub-id><pub-id pub-id-type="doi">10.1038/364121a0</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>BC</given-names></name><name><surname>Ye</surname><given-names>B</given-names></name><name><surname>Zackhary</surname><given-names>R</given-names></name><name><surname>Schrader</surname><given-names>K</given-names></name><name><surname>Seydoux</surname><given-names>G</given-names></name><name><surname>Reed</surname><given-names>RR</given-names></name></person-group><article-title>unc-3, a gene required for axonal guidance in Caenorhabditis elegans, encodes a member of the O/E family of transcription factors</article-title><source>Development</source><year>1998</year><volume>125</volume><fpage>1561</fpage><lpage>1568</lpage><pub-id pub-id-type="pmid">9502737</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kudrycki</surname><given-names>KE</given-names></name><name><surname>Buiakova</surname><given-names>O</given-names></name><name><surname>Tarozzo</surname><given-names>G</given-names></name><name><surname>Grillo</surname><given-names>M</given-names></name><name><surname>Walters</surname><given-names>E</given-names></name><name><surname>Margolis</surname><given-names>FL</given-names></name></person-group><article-title>Effects of mutation of the Olf-1 motif on transgene expression in olfactory receptor neurons</article-title><source>J Neurosci Res</source><year>1998</year><volume>52</volume><fpage>159</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">9579406</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-4547(19980415)52:2&#x0003c;159::AID-JNR4&#x0003e;3.0.CO;2-9</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devireddy</surname><given-names>LR</given-names></name><name><surname>Jones</surname><given-names>CJ</given-names></name></person-group><article-title>Olf-1, a neuron-specific transcription factor, can activate the herpes simplex virus type 1-infected cell protein 0 promoter</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">10617588</pub-id><pub-id pub-id-type="doi">10.1074/jbc.275.1.77</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baig</surname><given-names>S</given-names></name><name><surname>Olsson</surname><given-names>O</given-names></name><name><surname>Olsson</surname><given-names>T</given-names></name><name><surname>Love</surname><given-names>A</given-names></name><name><surname>Jeansson</surname><given-names>S</given-names></name><name><surname>Link</surname><given-names>H</given-names></name></person-group><article-title>Cells producing antibody to measles and herpes simplex virus in cerebrospinal fluid and blood of patients with multiple sclerosis and controls</article-title><source>Clin Exp Immunol</source><year>1989</year><volume>78</volume><fpage>390</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">2558823</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrante</surname><given-names>P</given-names></name><name><surname>Mancuso</surname><given-names>R</given-names></name><name><surname>Pagani</surname><given-names>E</given-names></name><name><surname>Guerini</surname><given-names>FR</given-names></name><name><surname>Calvo</surname><given-names>MG</given-names></name><name><surname>Saresella</surname><given-names>M</given-names></name><name><surname>Speciale</surname><given-names>L</given-names></name><name><surname>Caputo</surname><given-names>D</given-names></name></person-group><article-title>Molecular evidences for a role of HSV-1 in multiple sclerosis clinical acute attack</article-title><source>J Neurovirol</source><year>2000</year><volume>6</volume><fpage>S109</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">10871797</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poser</surname><given-names>CM</given-names></name><name><surname>Paty</surname><given-names>DW</given-names></name><name><surname>Scheinberg</surname><given-names>L</given-names></name><name><surname>McDonald</surname><given-names>WI</given-names></name><name><surname>Davis</surname><given-names>FA</given-names></name><name><surname>Ebers</surname><given-names>GC</given-names></name><name><surname>Johnson</surname><given-names>KP</given-names></name><name><surname>Sibley</surname><given-names>WA</given-names></name><name><surname>Silberberg</surname><given-names>DH</given-names></name><name><surname>Tourtellotte</surname><given-names>WW</given-names></name></person-group><article-title>New diagnostic criteria for multiple sclerosis: guidelines for research protocols</article-title><source>Ann Neurol</source><year>1983</year><volume>13</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">6847134</pub-id><pub-id pub-id-type="doi">10.1002/ana.410130302</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez Doncel</surname><given-names>A</given-names></name><name><surname>Rubio</surname><given-names>A</given-names></name><name><surname>Arroyo</surname><given-names>R</given-names></name><name><surname>de las Heras</surname><given-names>V</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Fernandez-Arquero</surname><given-names>M</given-names></name><name><surname>de la Concha</surname><given-names>EG</given-names></name></person-group><article-title>Interleukin-10 polymorphisms in Spanish multiple sclerosis patients</article-title><source>J Neuroimmunol</source><year>2002</year><volume>131</volume><fpage>168</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">12458048</pub-id><pub-id pub-id-type="doi">10.1016/S0165-5728(02)00248-5</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawcer</surname><given-names>S</given-names></name><name><surname>Ban</surname><given-names>M</given-names></name><name><surname>Maranian</surname><given-names>M</given-names></name><name><surname>Yeo</surname><given-names>TW</given-names></name><name><surname>Compston</surname><given-names>A</given-names></name><name><surname>Kirby</surname><given-names>A</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>De Jager</surname><given-names>PL</given-names></name><name><surname>Walsh</surname><given-names>E</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><etal></etal></person-group><article-title>A high-density screen for linkage in multiple sclerosis</article-title><source>Am J Hum Genet</source><year>2005</year><volume>77</volume><fpage>454</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">16080120</pub-id><pub-id pub-id-type="doi">10.1086/444547</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kenealy</surname><given-names>SJ</given-names></name><name><surname>Babron</surname><given-names>MC</given-names></name><name><surname>Bradford</surname><given-names>Y</given-names></name><name><surname>Schnetz-Boutaud</surname><given-names>N</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Rimmler</surname><given-names>JB</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Barcellos</surname><given-names>LF</given-names></name><name><surname>Lincoln</surname><given-names>RR</given-names></name><etal></etal></person-group><article-title>A second-generation genomic screen for multiple sclerosis</article-title><source>Am J Hum Genet</source><year>2004</year><volume>75</volume><fpage>1070</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">15494893</pub-id><pub-id pub-id-type="doi">10.1086/426459</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Serrano-Fernandez</surname><given-names>P</given-names></name><name><surname>Ibrahim</surname><given-names>SM</given-names></name><name><surname>Zettl</surname><given-names>UK</given-names></name><name><surname>Thiesen</surname><given-names>HJ</given-names></name><name><surname>Godde</surname><given-names>R</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name><name><surname>Moller</surname><given-names>S</given-names></name></person-group><article-title>Intergenomic consensus in multifactorial inheritance loci: the case of multiple sclerosis</article-title><source>Genes Immun</source><year>2004</year><volume>5</volume><fpage>615</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">15573086</pub-id><pub-id pub-id-type="doi">10.1038/sj.gene.6364134</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mansson</surname><given-names>R</given-names></name><name><surname>Tsapogas</surname><given-names>P</given-names></name><name><surname>Akerlund</surname><given-names>M</given-names></name><name><surname>Lagergren</surname><given-names>A</given-names></name><name><surname>Gisler</surname><given-names>R</given-names></name><name><surname>Sigvardsson</surname><given-names>M</given-names></name></person-group><article-title>Pearson correlation analysis of microarray data allows for the identification of genetic targets for early B-cell factor</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>17905</fpage><lpage>17913</lpage><pub-id pub-id-type="pmid">14960572</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M400589200</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maimone</surname><given-names>D</given-names></name><name><surname>Guazzi</surname><given-names>GC</given-names></name><name><surname>Annunziata</surname><given-names>P</given-names></name></person-group><article-title>IL-6 detection in multiple sclerosis brain</article-title><source>J Neurol Sci</source><year>1997</year><volume>146</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">9077497</pub-id><pub-id pub-id-type="doi">10.1016/S0022-510X(96)00283-3</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Navikas</surname><given-names>V</given-names></name><name><surname>Matusevicius</surname><given-names>D</given-names></name><name><surname>Soderstrom</surname><given-names>M</given-names></name><name><surname>Fredrikson</surname><given-names>S</given-names></name><name><surname>Kivisakk</surname><given-names>P</given-names></name><name><surname>Ljungdahl</surname><given-names>A</given-names></name><name><surname>Hojeberg</surname><given-names>B</given-names></name><name><surname>Link</surname><given-names>H</given-names></name></person-group><article-title>Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis</article-title><source>J Neuroimmunol</source><year>1996</year><volume>64</volume><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">8598391</pub-id><pub-id pub-id-type="doi">10.1016/0165-5728(95)00155-7</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname><given-names>Y</given-names></name><name><surname>Sakoda</surname><given-names>S</given-names></name><name><surname>Saeki</surname><given-names>Y</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name><name><surname>Yanagihara</surname><given-names>T</given-names></name></person-group><article-title>Enhancement of Th2 response in IL-6-deficient mice immunized with myelin oligodendrocyte glycoprotein</article-title><source>J Neuroimmunol</source><year>2000</year><volume>105</volume><fpage>120</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">10742553</pub-id><pub-id pub-id-type="doi">10.1016/S0165-5728(00)00192-2</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>Neurodegenerative tauopathies</article-title><source>Annu Rev Neurosci</source><year>2001</year><volume>24</volume><fpage>1121</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">11520930</pub-id><pub-id pub-id-type="doi">10.1146/annurev.neuro.24.1.1121</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebneth</surname><given-names>A</given-names></name><name><surname>Godemann</surname><given-names>R</given-names></name><name><surname>Stamer</surname><given-names>K</given-names></name><name><surname>Illenberger</surname><given-names>S</given-names></name><name><surname>Trinczek</surname><given-names>B</given-names></name><name><surname>Mandelkow</surname><given-names>E</given-names></name></person-group><article-title>Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease</article-title><source>J Cell Biol</source><year>1998</year><volume>143</volume><fpage>777</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">9813097</pub-id><pub-id pub-id-type="doi">10.1083/jcb.143.3.777</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapaki</surname><given-names>E</given-names></name><name><surname>Paraskevas</surname><given-names>GP</given-names></name><name><surname>Michalopoulou</surname><given-names>M</given-names></name><name><surname>Kilidireas</surname><given-names>K</given-names></name></person-group><article-title>Increased cerebrospinal fluid tau protein in multiple sclerosis</article-title><source>Eur Neurol</source><year>2000</year><volume>43</volume><fpage>228</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">10828654</pub-id><pub-id pub-id-type="doi">10.1159/000008181</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>A</given-names></name><name><surname>Araujo</surname><given-names>GW</given-names></name><name><surname>Trajkovic</surname><given-names>K</given-names></name><name><surname>Herrmann</surname><given-names>MM</given-names></name><name><surname>Merkler</surname><given-names>D</given-names></name><name><surname>Mandelkow</surname><given-names>EM</given-names></name><name><surname>Weissert</surname><given-names>R</given-names></name><name><surname>Simons</surname><given-names>M</given-names></name></person-group><article-title>Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>55833</fpage><lpage>55839</lpage><pub-id pub-id-type="pmid">15494405</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M409954200</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stokin</surname><given-names>GB</given-names></name><name><surname>Lillo</surname><given-names>C</given-names></name><name><surname>Falzone</surname><given-names>TL</given-names></name><name><surname>Brusch</surname><given-names>RG</given-names></name><name><surname>Rockenstein</surname><given-names>E</given-names></name><name><surname>Mount</surname><given-names>SL</given-names></name><name><surname>Raman</surname><given-names>R</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Williams</surname><given-names>DS</given-names></name><etal></etal></person-group><article-title>Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease</article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>1282</fpage><lpage>1288</lpage><pub-id pub-id-type="pmid">15731448</pub-id><pub-id pub-id-type="doi">10.1126/science.1105681</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Surinya</surname><given-names>KH</given-names></name><name><surname>Cox</surname><given-names>TC</given-names></name><name><surname>May</surname><given-names>BK</given-names></name></person-group><article-title>Identification and characterization of a conserved erythroid-specific enhancer located in intron 8 of the human 5-aminolevulinate synthase 2 gene</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>16798</fpage><lpage>16809</lpage><pub-id pub-id-type="pmid">9642238</pub-id><pub-id pub-id-type="doi">10.1074/jbc.273.27.16798</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghayor</surname><given-names>C</given-names></name><name><surname>Herrouin</surname><given-names>JF</given-names></name><name><surname>Chadjichristos</surname><given-names>C</given-names></name><name><surname>Ala-Kokko</surname><given-names>L</given-names></name><name><surname>Takigawa</surname><given-names>M</given-names></name><name><surname>Pujol</surname><given-names>JP</given-names></name><name><surname>Galera</surname><given-names>P</given-names></name></person-group><article-title>Regulation of human COL2A1 gene expression in chondrocytes. Identification of C-Krox-responsive elements and modulation by phenotype alteration</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>27421</fpage><lpage>27438</lpage><pub-id pub-id-type="pmid">10856292</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>K</given-names></name><name><surname>Ohnishi</surname><given-names>Y</given-names></name><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Sekine</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Hori</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name></person-group><article-title>Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction</article-title><source>Nat Genet</source><year>2002</year><volume>32</volume><fpage>650</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">12426569</pub-id><pub-id pub-id-type="doi">10.1038/ng1047</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tokuhiro</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Kochi</surname><given-names>Y</given-names></name><name><surname>Sawada</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Nagasaki</surname><given-names>M</given-names></name><name><surname>Ohtsuki</surname><given-names>M</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis</article-title><source>Nat Genet</source><year>2003</year><volume>35</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">14608356</pub-id><pub-id pub-id-type="doi">10.1038/ng1267</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villar</surname><given-names>LM</given-names></name><name><surname>Masjuan</surname><given-names>J</given-names></name><name><surname>Gonzalez-Porque</surname><given-names>P</given-names></name><name><surname>Plaza</surname><given-names>J</given-names></name><name><surname>Sadaba</surname><given-names>MC</given-names></name><name><surname>Roldan</surname><given-names>E</given-names></name><name><surname>Bootello</surname><given-names>A</given-names></name><name><surname>Alvarez-Cermeno</surname><given-names>JC</given-names></name></person-group><article-title>Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis</article-title><source>Ann Neurol</source><year>2003</year><volume>53</volume><fpage>222</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">12557289</pub-id><pub-id pub-id-type="doi">10.1002/ana.10441</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villar</surname><given-names>LM</given-names></name><name><surname>Sadaba</surname><given-names>MC</given-names></name><name><surname>Roldan</surname><given-names>E</given-names></name><name><surname>Masjuan</surname><given-names>J</given-names></name><name><surname>Gonzalez-Porque</surname><given-names>P</given-names></name><name><surname>Villarrubia</surname><given-names>N</given-names></name><name><surname>Espino</surname><given-names>M</given-names></name><name><surname>Garcia-Trujillo</surname><given-names>JA</given-names></name><name><surname>Bootello</surname><given-names>A</given-names></name><name><surname>Alvarez-Cermeno</surname><given-names>JC</given-names></name></person-group><article-title>Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS</article-title><source>J Clin Invest</source><year>2005</year><volume>115</volume><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">15630459</pub-id><pub-id pub-id-type="doi">10.1172/JCI200522833</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sellebjerg</surname><given-names>F</given-names></name><name><surname>Christiansen</surname><given-names>M</given-names></name><name><surname>Garred</surname><given-names>P</given-names></name></person-group><article-title>MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis</article-title><source>Mult Scler</source><year>1998</year><volume>4</volume><fpage>127</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">9762660</pub-id><pub-id pub-id-type="doi">10.1191/135245898678909475</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>RJ</given-names></name><name><surname>Singhrao</surname><given-names>SK</given-names></name><name><surname>Neal</surname><given-names>JW</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name><name><surname>Morgan</surname><given-names>BP</given-names></name></person-group><article-title>The membrane attack complex of complement causes severe demyelination associated with acute axonal injury</article-title><source>J Immunol</source><year>2002</year><volume>168</volume><fpage>458</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">11751993</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uccelli</surname><given-names>A</given-names></name><name><surname>Aloisi</surname><given-names>F</given-names></name><name><surname>Pistoia</surname><given-names>V</given-names></name></person-group><article-title>Unveiling the enigma of the CNS as a B-cell fostering environment</article-title><source>Trends Immunol</source><year>2005</year><volume>26</volume><fpage>254</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">15866238</pub-id><pub-id pub-id-type="doi">10.1016/j.it.2005.02.009</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akerblad</surname><given-names>P</given-names></name><name><surname>Lind</surname><given-names>U</given-names></name><name><surname>Liberg</surname><given-names>D</given-names></name><name><surname>Bamberg</surname><given-names>K</given-names></name><name><surname>Sigvardsson</surname><given-names>M</given-names></name></person-group><article-title>Early B-cell factor (O/E-1) is a promoter of adipogenesis and involved in control of genes important for terminal adipocyte differentiation</article-title><source>Mol Cell Biol</source><year>2002</year><volume>22</volume><fpage>8015</fpage><lpage>8025</lpage><pub-id pub-id-type="pmid">12391167</pub-id><pub-id pub-id-type="doi">10.1128/MCB.22.22.8015-8025.2002</pub-id></citation></ref></ref-list></back></article> 